CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the ...
LIB, a home energy brand dedicated exclusively to the home, has launched in the Australian market with the debut of its first ...
Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels. The injectable product has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results